399 related articles for article (PubMed ID: 28323004)
1. Fresh or Cryopreserved CD34
Ghobadi A; Fiala MA; Ramsingh G; Gao F; Abboud CN; Stockerl-Goldstein K; Uy GL; Grossman BJ; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1072-1077. PubMed ID: 28323004
[TBL] [Abstract][Full Text] [Related]
2. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.
Gómez-Almaguer D; Gómez-Peña Á; Jaime-Pérez JC; Gómez-Guijosa MÁ; Cantú-Rodríguez O; Gutiérrez-Aguirre H; Martínez-Cabriales SA; García-Rodríguez F; Olguín-Ramírez LA; Salazar-Riojas R; Méndez-Ramírez N
J Clin Apher; 2013 Oct; 28(5):349-55. PubMed ID: 23682006
[TBL] [Abstract][Full Text] [Related]
3. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
[TBL] [Abstract][Full Text] [Related]
4. Durable Engraftment and Excellent Overall Survival After CD34-Selected Peripheral Blood Stem Cell Boost in Pediatric Patients With Poor Graft Function Following Allogeneic Stem Cell Transplantation.
Fraint E; Farooki S; Klein E; Mauguen A; Prockop SE; Scaradavou A; Curran K; Cancio M; Spitzer B; Boelens JJ; Oved J; Harris A; O'Reilly RJ; Kernan NA
Transplant Cell Ther; 2023 Jan; 29(1):46.e1-46.e6. PubMed ID: 36210027
[TBL] [Abstract][Full Text] [Related]
5. Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.
Haen SP; Schumm M; Faul C; Kanz L; Bethge WA; Vogel W
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2241-51. PubMed ID: 26272482
[TBL] [Abstract][Full Text] [Related]
6. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
[TBL] [Abstract][Full Text] [Related]
7. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
8. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Shahzad M; Siddiqui RS; Anwar I; Chaudhary SG; Ali T; Naseem M; Ahmed TF; Ahmed Z; Khurana S; Ahmed N; Balusu R; Singh AK; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
Transplant Cell Ther; 2021 Oct; 27(10):877.e1-877.e8. PubMed ID: 34284148
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
[TBL] [Abstract][Full Text] [Related]
10. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation.
Larocca A; Piaggio G; Podestà M; Pitto A; Bruno B; Di Grazia C; Gualandi F; Occhini D; Raiola AM; Dominietto A; Bregante S; Lamparelli T; Tedone E; Oneto R; Frassoni F; Van Lint MT; Pogliani E; Bacigalupo A
Haematologica; 2006 Jul; 91(7):935-40. PubMed ID: 16818281
[TBL] [Abstract][Full Text] [Related]
11. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.
Klyuchnikov E; El-Cheikh J; Sputtek A; Lioznov M; Calmels B; Furst S; Chabannon C; Crocchiolo R; Lemarié C; Faucher C; Bacher U; Alchalby H; Stübig T; Wolschke C; Ayuk F; Reckhaus ML; Blaise D; Kröger N
Biol Blood Marrow Transplant; 2014 Mar; 20(3):382-6. PubMed ID: 24321747
[TBL] [Abstract][Full Text] [Related]
12. CD34
Mainardi C; Ebinger M; Enkel S; Feuchtinger T; Teltschik HM; Eyrich M; Schumm M; Rabsteyn A; Schlegel P; Seitz C; Schwarze CP; Müller I; Greil J; Bader P; Schlegel PG; Martin D; Holzer U; Döring M; Handgretinger R; Lang P
Br J Haematol; 2018 Jan; 180(1):90-99. PubMed ID: 29205259
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.
Chen YB; Le-Rademacher J; Brazauskas R; Kiefer DM; Hamadani M; DiPersio JF; Litzow MR; Craig M; Horwitz ME; Artz AS; McClune BL; Fernandez HF; Duong HK; Kobusingye H; Proue M; Drexler RJ; Horowitz MM; Shaw BE; Miller JP; Hosoba S; Waller EK; Devine SM
Blood Adv; 2019 Mar; 3(6):875-883. PubMed ID: 30890544
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
[TBL] [Abstract][Full Text] [Related]
17. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
18. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
Chen J; Yuan LL; Zhang X; Qiao JL; Yin QX; Zhang YM; Yang XL; Cao XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
